DARE — Dare Bioscience, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1401914 ·
Last close
$0.43
Market Cap
$8.44M
52W High
$3.78
52W Low
$0.41
ADV30
162,496
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 47,628 | -132,851 | -3,092,145 | -3,157,936 | 22,098,552 | 11,531,684 | 19,757,177 |
| Jun 2026 | 187,546 | -132,343 | -2,967,980 | -2,982,773 | 22,370,109 | 12,617,594 | 22,930,209 |
| Mar 2026 | 152,455 | -89,870 | -2,998,898 | -2,999,889 | 27,828,414 | 18,519,784 | 27,093,963 |
| Dec 2025 | 1,023,676 | 727,877 | -1,471,268 | -1,441,718 | 32,474,563 | 24,711,356 | 29,631,929 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,293,561
Investing CF
$-461,929
Financing CF
$19,310,108
CapEx
$-538,674
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.14
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-194,671,566
Inventory
—
Receivables
$456,429
ST Investments
—
EBIT TTM
$-11,110,294
Pretax Income TTM
$-10,987,146
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,365,939
EBITDA
$-8,978,829
Free Cash Flow
$-6,908,168
Enterprise Value
$4,941,179
Total Cash
$12,617,594
Total Debt
$6,763,626
Shares Out
19,669,083
Trailing EPS
$-0.66
Book Value
$-0.04
ROE
—
ROA
-39.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,030,193 | -13,552,334 | -13,399,274 | 32,474,563 | 29,631,929 | 2,842,634 | -9,885,870 |
| Dec 2024 | 9,784 | -23,451,485 | -4,053,599 | 22,101,131 | 28,113,220 | -6,012,089 | 5,473,555 |
| Dec 2023 | 2,807,885 | -30,939,880 | -30,161,391 | 21,282,215 | 26,329,855 | -5,047,640 | -38,856,654 |
| Dec 2022 | 10,000,000 | -31,385,488 | -30,947,738 | 43,826,383 | 32,714,273 | 11,112,110 | -18,088,429 |
TTM Snapshot
Revenues TTM
$1,365,939
NetIncome TTM
$-10,987,146
OpCashFlow TTM
—
Assets (Latest)
$22,370,109
Forward EPS
$-0.41
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CALC | CalciMedica, Inc. | $8.41M | $1.22 | — |
| VTGN | Vistagen Therapeutics, Inc. | $8.34M | $0.19 | — |
| PHIO | Phio Pharmaceuticals Corp. | $8.57M | $0.72 | — |
| KYNB | KYNTRA BIO, INC. | $8.26M | $2.04 | — |
| MTVA | MetaVia Inc. | $8.24M | $1.25 | — |
News headlines (Yahoo Finance, 1h cache)
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates
2026-11-16 21:15 · Yahoo
Daré Bioscience Receives Approximately $852,000 in Additional Grant Funding
2026-11-16 14:09 · Yahoo
Daré Bioscience to Host Third Quarter 2026 Financial Results and Company Update Conference Call and Webcast on November 16, 2026
2026-11-10 14:00 · Yahoo
Daré Bioscience Releases Next Episode in “CEO Corner” Video Series
2026-11-09 14:01 · Yahoo
Daré Bioscience to Present at Stifel’s 2026 Healthcare Conference
2026-11-04 14:05 · Yahoo
Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum
2026-10-30 12:32 · Yahoo
Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
2026-10-26 12:32 · Yahoo
Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
2026-10-19 12:56 · Yahoo
Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities
2026-10-13 13:15 · Yahoo
Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting
2026-10-08 13:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.